Neurocrine Biosciences | NBIX - Ebitda





Ebitda Cambiamento Data
AbbVie USD 5.37B 1.85B 2025-12
Acadia Pharmaceuticals USD 35.76M 447K 2025-09
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
ALKERMES USD 100.31M 21.24M 2025-12
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
Biogen USD 573.2M 253.7M 2025-12
BioMarin Pharmaceutical USD -24.17M 18.91M 2025-12
Cytokinetics USD -277.18M 169.36M 2025-09
Exelixis USD 248.93M 28.02M 2025-09
Gilead Sciences USD 3.02B 1.01B 2025-12
Halozyme Therapeutics USD 21.9M 226.34M 2025-12
Incyte USD 414.5M 92.42M 2025-12
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Pfizer USD 6.08B 351M 2025-09
Prothena USD -39.53M 12.25M 2025-09
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Repligen USD 39.54M 3.61M 2025-12
Rigel Pharmaceuticals USD -4.17M 798K 2023-09
Sarepta Therapeutics USD -168.03M 294.45M 2025-09
Teva Pharmaceutical Industries USD 1.06B 582M 2026-03
Ultragenyx Pharmaceutical USD -156.79M 65.44M 2025-09
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09
Xoma USD 2.52M 7.98M 2024-06